Natural Health Trends Corp. — 2012 Form 10-K
Reporting period: Fiscal year ended December 31, 2012. This filing reports full-year results, not standalone fourth-quarter results. Financial amounts are in U.S. dollars; statement figures are generally in thousands unless noted.
Business context
Natural Health Trends sells NHT Global wellness, skincare and lifestyle products through direct selling and e-commerce. It reported one operating segment. Its business is highly international: Hong Kong accounted for 69.9% of 2012 net sales, and most Hong Kong sales were delivered to members in China. Active distributors increased to 20,680 from 18,410.
Financial performance and liquidity
| Metric | 2012 | 2011 | Change |
|---|---|---|---|
| Net sales | $37.514 million | $31.162 million | +20% |
| Gross profit / margin | $27.829 million / 74.2% | $22.990 million / 73.8% | Margin +0.4 percentage points |
| Operating income / margin | $2.645 million / 7.1% | $1.783 million / 5.8% | Margin +1.3 points |
| Net income | $2.630 million | $2.425 million | +8% |
| Net income attributable to common stockholders | $2.613 million; diluted EPS $0.23 | $2.289 million; diluted EPS $0.21 | |
| Cash from operating activities | $2.214 million | $1.463 million | Increased |
Cash and cash equivalents were $4.207 million at year-end, up from $1.617 million. Current assets were $5.837 million and current liabilities $6.310 million, producing a $473,000 working-capital deficit and a 0.93 current ratio. Excluding $836,000 of deferred revenue, the current ratio was 1.07. Total stockholders’ equity improved to $1.909 million from a $809,000 deficit. The balance sheet reports no borrowing balance; the filing says no significant financing activities occurred in 2012.
Material changes and management commentary
- Hong Kong sales rose 25% to $26.235 million, attributed by management to renewed training, leadership alignment and recognition incentives. Russia sales increased 22% to $5.540 million, supported by incentive trips and promotions.
- Distributor commissions rose to 41.9% of sales from 38.0%, reflecting Hong Kong recognition-program costs and higher payout in Hong Kong and Russia. SG&A was $9.415 million, up $363,000, while total operating expenses declined as a percentage of sales.
- Gross margin improved with lower expedited freight costs and price increases for Noni in Hong Kong and products in North America, along with introduction of higher-margin Hong Kong products.
- Foreign exchange shifted from a $226,000 gain in 2011 to a $125,000 loss in 2012. The 2011 tax benefit was $298,000, compared with $24,000 in 2012; management cited prior-year tax-liability reversals.
- Management expects existing cash and operating cash flows to fund normal operations and commitments for at least 12 months, assuming no significant unforeseen expense or revenue decline. No quantified revenue or earnings guidance is provided.
Risks, contingencies and unusual items
- China and Hong Kong concentration: China-related regulation is uncertain, the company lacks a Chinese direct-selling license, and authorities have scrutinized activity; enforcement could cause fines, interruptions or business-model changes. Hong Kong’s concentration makes disruption there especially consequential.
- Distributor economics: The business relies on independent distributors and a small group of key leaders. Commission expense is substantial and increased in 2012; higher payouts can constrain profitability.
- Products and suppliers: Four product lines account for a significant majority of sales, with limited supplier alternatives and no long-term contract with one major vendor. Supply interruption or product-quality issues could materially affect results.
- Other exposures: Foreign currency, direct-selling and product regulation, product claims and liability, competition, and reliance on information technology and third-party cloud infrastructure are significant risks. The company states it does not carry direct product-liability insurance.
- Potential dilution: Warrants and convertible preferred stock remain outstanding. The filing reports 3,704,854 warrants outstanding at year-end and describes anti-dilution provisions on certain warrants. Series A preferred stock has a $329,000 liquidation value and $174,000 of accrued unpaid dividends.
- Related-party arrangement: A February 2013 license with director George Broady’s company provides for a 2.5% royalty on Restor sales; the company was also considering a similar arrangement for Soothe. The filing reports no legal proceedings and no year-end severance obligations.
The independent auditor issued an unqualified opinion on the consolidated financial statements. Management concluded that disclosure controls and internal control over financial reporting were effective at December 31, 2012; the auditor did not attest to internal-control effectiveness.
Important facts for investors to verify
- Whether China-related regulatory developments affect Hong Kong-based sales delivered to Chinese members, and the status of any direct-selling license application.
- Whether sales growth and distributor activity can be sustained while commission expense remains elevated.
- Cash conversion, working-capital needs and the company’s ability to meet operating commitments if sales weaken.
- Concentration of sales in a few products and suppliers, including contract terms and alternative sourcing options.
- Potential dilution, warrant exercise and preferred-stock rights, as well as the final terms and oversight of related-party royalty arrangements.